Case study

A 730-Day Enrollment Window, Reshaped Before Day One

A top-10 pharma sponsor's aggressive Phase III cardiovascular timeline, modeled head-to-head against real-world data — surfacing a diversified country mix that cut 118 days to LPI and raised success odds from 85% to 94%.

Enrollment

Get the full case study

Free PDF. Straight to your inbox.

The results

~94%

Validated feasibility

-118 days

Reduced timeline (LPI)

+2 markets

Optimized selection

-9%

Screen-failed exposure

Inside the case study

01

The challenge

A top-10 pharma sponsor's Phase III cardiovascular program faced an aggressive enrollment timeline with limited confidence in its country and site allocation strategy.
02

The approach

Using Enrollment Forecaster, the team stress-tested the original plan against real-world enrollment data and ran scenario models across alternative country mixes.
03

The outcome

A diversified country allocation cut projected time to last-patient-in (LPI) by 118 days and raised enrollment success probability from 85% to 94%—giving the sponsor a defensible, data-backed plan ahead of study start.

See how they did it

The full case study, straight to your inbox. Nothing beyond your email address.

Get the case study